Silvia Fanello

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis

Tiziana Pressiani, C. Boni, Lorenza Rimassa et al. · Annals of Oncology · 2012 · 152 citations · Full text

Medicine, Oncology, Hepatic Pharmacokinetics +12

Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly et al. · Journal of Clinical Oncology · 2022 · 132 citations · Full text

Medicine, Oncology, Pharmacology +13

Expression of <scp>pERK</scp> and <scp>VEGFR</scp>‐2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment

Francesca Negri, Barbara Dal Bello, Camillo Porta et al. · Liver International · 2015 · 59 citations

Medicine, Oncology, Pharmacology +17

The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib

Luca Faloppi, Maristella Bianconi, Riccardo Giampieri et al. · Oncotarget · 2015 · 46 citations · Full text

Medicine, Oncology, Pharmacology +10